Media Center

Archives: Press Release

Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer

WALTHAM, Mass. — April 10, 2017 — Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced the appointment of Mike Gutch, Ph.D., as Chief Financial Officer and Chief Business Officer. Dr. Gutch has extensive experience as a business executive in the biotechnology and pharmaceutical industries as well […]

Entasis Therapeutics Announces Partnership with CARB-X to Support Development of Oral, Gram-negative Program

Entasis Awarded up to $6.3MM to Develop its Oral Agent for the Treatment of Multi-drug Resistant Gram-negative Infections, Including Those Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) WALTHAM, Mass. — March 30, 2017 — Entasis Therapeutics Inc., a company focused on the discovery and development of breakthrough anti-infective products, today announced that it has entered into a […]

Entasis Therapeutics Names Greg Norden, Former Senior Vice President and Chief Financial Officer of Wyeth, to its Board of Directors

WALTHAM, Mass. — November 29, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, announced today the appointment of Greg Norden to the company’s Board of Directors. “Greg is an outstanding leader in our industry, and I am delighted to welcome him to our Board,” said Manos Perros, […]

Entasis Therapeutics to Present Data at IDWeek on ETX2514SUL, a Novel Drug Targeting Multidrug-Resistant Acinetobacter baumannii Infections

Data also to be Presented on EXT0914, a Novel Drug Targeting Gonorrhea WALTHAM, Mass. — October 28, 2016 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced that it will present four posters at IDWeek 2016™, which is being held from October 26 – 30 in New Orleans. […]

Entasis Announces Initiation of Phase I Clinical Trial of ETX2514

ETX2514 in Combination with Sulbactam is Being Developed for the Treatment of Serious Drug-Resistant Hospital Infections WALTHAM, Mass. — October 26, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced initiation of a Phase 1 clinical study of ETX2514. The study will evaluate the safety, tolerability […]

Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

Validates Company’s Pathogen-targeted Discovery and Development Platform WALTHAM, Mass. — September 21, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that data from a Phase 2 study of ETX0914, the Company’s novel oral antibiotic compound, will be presented at the 2016 STD Prevention Conference in […]

Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016

New Drug Combination Demonstrates Activity Against Acinetobacter baumannii, a Multi-drug Resistant Pathogen and a Global Health Threat                WALTHAM, Mass. — June 28, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that preclinical data on ETX2514, a next-generation beta-lactamase inhibitor […]

Entasis to Present Preclinical Data on ETX2514, a Next-Generation Beta-lactamase Inhibitor, at ASM Microbe 2016

WALTHAM, Mass. — June 15, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced that preclinical data from ETX2514, a next-generation beta-lactamase inhibitor, will be presented at the first annual American Society for Microbiology (ASM) Microbe 2016 conference taking place June 16 through 20, 2016 in […]

Entasis Announces $50 Million Series B Financing led by Clarus

Proceeds will Advance Pipeline of Innovative Anti-infective Products WALTHAM, Mass. — April 4, 2016 — Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, today announced the completion of a $50 million Series B financing to advance its pipeline of clinical and preclinical products. The financing was led by Clarus […]

Entasis Announces Appointments to its Scientific and Clinical Advisory Board

WALTHAM, Mass. — December 15, 2015 — Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials, today announced the formation of the company’s Scientific and Clinical Advisory Board, comprised of experts in infectious diseases. The Advisory Board will provide strategic guidance on Entasis’ pipeline of preclinical […]